Found 286 articles for: "biologics"
Systematic Review of Vismodegib Toxicity Profile in the Treatment of Advanced Basal Cell Carcinomas Compared to Other Systemic Therapies in Dermatology
June 2014 | Volume 13 | Issue 6 | Original Article | 729 | Copyright © June 2014
Vismodegib is a first-in-class, hedgehog-signal inhibitor that is FDA-approved for use with advanced basal cell carcinomas (BCCs) that cannot be removed by either surgical resection or treated with ra...
Read MoreClinical Equivalence of Conventional OnabotulinumtoxinA (900 KDa) and IncobotulinumtoxinA (Neurotoxin Free From Complexing Proteins - 150 KDa): 2013 Multidisciplinary French Consensus in Aesthetics
December 2013 | Volume 12 | Issue 12 | Original Article | 1434 | Copyright © December 2013
Botulinum neurotoxins are the most popular non-surgical treatments for aesthetic indications, but there is uncertainty about whether certain formulations are comparable in efficacy and safety and can...
Read MoreImmune Response to Pneumococcus and Tetanus Toxoid in Patients With Moderate-to-Severe Psoriasis Following Long-Term Ustekinumab Use
October 2013 | Volume 12 | Issue 10 | Original Article | 1122 | Copyright © October 2013
BACKGROUND: Little is known about the impact of long-term use of immunosuppressive agents on immune response.
OBJECTIVES: Assess the impact of continuous maintenance ustekinumab treatment on pa...
Read MoreCombination Use of Ustekinumab With Other Systemic Therapies: A Retrospective Study in a Tertiary Referral Center
October 2013 | Volume 12 | Issue 10 | Original Article | 1098 | Copyright © October 2013
BACKGROUND: Patients with moderate to severe psoriasis may not respond adequately to single systemic agent and may require combination systemic therapy.
OBJECTIVE: To evaluate the prevalence, i...
Read MorePsoriasis Treatments by Payment Type in the US Outpatient Office Setting
October 2013 | Volume 12 | Issue 10 | Original Article | 1095 | Copyright © October 2013
BACKGROUND: Many factors, including patients' methods of payment, may influence psoriasis treatment decisions.
OBJECTIVE: To characterize psoriasis treatments by patients' types of payment in t...
Read MoreAdherence to Ustekinumab in Psoriasis Patients
October 2013 | Volume 12 | Issue 10 | Original Article | 1090 | Copyright © October 2013
BACKGROUND: Adherence to the treatment of psoriasis is poor and effects treatment outcomes. Literature on adherence to biologic therapy for the treatment of psoriasis is limited and difficult to measu...
Read MorePossible Drug-Drug Interaction Between Adalimumab and Duloxetine and/or Pregabalin in a Psoriasis Patient
October 2013 | Volume 12 | Issue 10 | Editorials | 1089 | Copyright © October 2013
Effectiveness of Systemic Treatment Agents on Psoriatic Nails: A Comparative Study
September 2013 | Volume 12 | Issue 9 | Original Article | 1039 | Copyright © September 2013
BACKGROUND: Nails, one of the most visible sites of body, are frequently involved in psoriasis and accepted as the most difficult site for topical treatment because of their anatomical structure. Heal...
Read MoreInfliximab-Induced Psoriasis in Treatment of Crohn's Disease-Associated Ankylosing Spondylitis: Case Report and Review of 142 Cases
August 2013 | Volume 12 | Issue 8 | Original Article | 939 | Copyright © August 2013
TNF-alpha inhibitors are used to treat numerous inflammatory conditions including rheumatoid arthritis and inflammatory bowel disease. Recent reports have illustrated the paradoxical development of ps...
Read MoreEfficacy, Tolerability, and Pharmacodynamics of Apremilast in Recalcitrant Plaque Psoriasis: A Phase II Open-Label Study
August 2013 | Volume 12 | Issue 8 | Original Article | 888 | Copyright © August 2013
BACKGROUND: Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II, multicenter, open...
Read MoreEffect of Calcipotriene Plus Betamethasone Dipropionate Topical Suspension on the Hypothalamic-Pituitary-Adrenal Axis and Calcium Homeostasis in Subjects With Extensive Psoriasis Vulgaris: An Open, Non-Controlled, 8-week Trial
August 2013 | Volume 12 | Issue 8 | Original Article | 882 | Copyright © August 2013
BACKGROUND: The two-compound topical suspension/gel containing calcipotriene plus betamethasone dipropionate is effective and safe in the treatment of psoriasis on the body and scalp within the genera...
Read MoreComparison of the Efficacy of Biologics Versus Conventional Systemic Therapies in the Treatment of Psoriasis at a Comprehensive Psoriasis Care Center
August 2013 | Volume 12 | Issue 8 | Original Article | 861 | Copyright © August 2013
BACKGROUND: The efficacy of biologic treatment for psoriasis has not been compared to that of conventional systemic therapies and phototherapy outside of clinical trial settings.
DESIGN: Retros...
Read MoreA Double-Blind, Randomized Clinical Trial of 20% Alpha/Poly Hydroxy Acid Cream to Reduce Scaling of Lesions Associated With Moderate, Chronic Plaque Psoriasis
August 2013 | Volume 12 | Issue 8 | Original Article | 855 | Copyright © August 2013
BACKGROUND: Salicylic acid is a topical keratolytic agent used to reduce scaling and hyperkeratosis associated with psoriasis vulgaris. However, its use is limited due to potential systemic toxicity. ...
Read MoreThe Continued Evolution of Drugs for Psoriasis
August 2013 | Volume 12 | Issue 8 | Editorials | 850 | Copyright © August 2013
Pipeline Previews
July 2013 | Volume 12 | Issue 7 | Features | 833 | Copyright © July 2013
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from th...
Read MoreIncobotulinumtoxinA in Esthetics
June 2013 | Volume 12 | Issue 6 | Original Article | 111 | Copyright © June 2013
IncobotulinumtoxinA (Xeomin®/Xeomeen®/Bocouture®/XEOMIN Cosmetic™) is a botulinum toxin type A that differs from other commercially available botulinum toxin type A preparations in that it is fr...
Read MoreNews, Views, & Reviews
Hair Loss in the Dermatology Office: An Update on Alopecia AreataMay 2013 | Volume 12 | Issue 5 | Features | 588 | Copyright © May 2013
Combination Therapy for Psoriasis in the United States
May 2013 | Volume 12 | Issue 5 | Original Article | 546 | Copyright © May 2013
BACKGROUND: Psoriasis is treated with several classes of treatments that may be used in combination, but the ways combination therapies are used are not well characterized.
PURPOSE: To determine...
Read MoreInfections Associated With the Use of Tumor Necrosis Factor-α Inhibitors in Psoriasis
March 2013 | Volume 12 | Issue 3 | Original Article | 41 | Copyright © March 2013
Tumor necrosis factor (TNF)-α inhibitors have been shown to increase the risks of overall infection and serious infection in rheumatoid arthritis. However, it is uncertain whether we can draw th...
Read MoreThe Efficacy of Ustekinumab in Psoriasis
March 2013 | Volume 12 | Issue 3 | Original Article | 317 | Copyright © March 2013
Psoriasis is an immune-mediated cutaneous disease affecting 2% of the worldwide population. While topical therapy, phototherapy, oral systemic therapy, and biologic agents have been used, the treatmen...
Read More